Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
D054598:Blue Cross Blue Shield Insurance Plans; D002986:Clinical Trials as Topic; D019937:Diagnostic Techniques and Procedures; D057069:Diagnostic Test Approval; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D058990:Molecular Targeted Therapy; D009154:Mutation; D018579:Patient Selection; D010597:Pharmacogenetics; D057285:Precision Medicine; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D013673:Technology Assessment, Biomedical; D014481:United States; D014486:United States Food and Drug Administration
D048493:Proto-Oncogene Proteins B-raf